Use of illicit substances and violent behaviour in psychotic disorders: two nationwide case-control studies and meta-analyses

Jelle Lamsma1,2, Wiepke Cahn2, Seena Fazel1* and GROUP and NEDEN investigators*

1Department of Psychiatry, University of Oxford, Oxford, UK and 2Department of Psychiatry, University Medical Centre Utrecht, Utrecht, the Netherlands

Abstract

Background. Substance use disorder explains much of the excess risk of violent behaviour in psychotic disorders. However, it is unclear to what extent the pharmacological properties and subthreshold use of illicit substances are associated with violence.

Methods. Individuals with psychotic disorders were recruited for two nationwide projects: GROUP (N = 871) in the Netherlands and NEDEN (N = 921) in the United Kingdom. Substance use and violent behaviour were assessed with standardized instruments and multiple sources of information. First, we used logistic regression models to estimate the associations of daily and nondaily use with violence for cannabis, stimulants, depressants and hallucinogens in the GROUP and NEDEN samples separately. Adjustments were made for age, sex and educational level. We then combined the results in random-effects meta-analyses.

Results. Daily use, compared with nondaily or no use, and nondaily use, compared with no use, increased the pooled odds of violence in people with psychotic disorders for all substance categories. The increases were significant for daily use of cannabis (pooled odds ratio (pOR) 1.6, 95% confidence interval (CI) 1.2–2.0), stimulants (pOR 2.8, 95% CI 1.7–4.5) and depressants (pOR 2.2, 95% CI 1.1–4.5), and nondaily use of stimulants (pOR 1.6, 95% CI 1.2–2.0) and hallucinogens (pOR 1.5, 95% CI 1.1–2.1). Daily use of hallucinogens, which could only be analysed in the NEDEN sample, significantly increased the risk of violence (adjusted odds ratio 3.3, 95% CI 1.2–9.3).

Conclusions. Strategies to prevent violent behaviour in psychotic disorders should target any substance use.

Introduction

Much of the excess risk of violent behaviour in psychotic disorders can be explained by substance use disorder (SUD) (Fazel et al., 2009). In a meta-analysis of 16 studies with a total of 5365 cases, SUD more than doubled the odds of violence [odds ratio (OR) 2.2, 95% confidence interval (CI) 1.6–2.9] (Witt et al., 2013).

However, it is unclear to what extent different categories of illicit substances, as defined by their psychopharmacological effects, are related to violent behaviour. Another uncertainty is whether subthreshold use, as opposed to SUD, is a risk factor for violence. These questions may be clinically relevant, as the psychopharmacological properties of substances modify violence risk in the general population (Tomlinson et al., 2016) and people with psychotic disorders are highly sensitive to the harmful effects of substances (Gregg et al., 2007). The few studies of cannabis (Koen et al., 2004; Moulin et al., 2018; Oluwoye et al., 2019) and stimulants (Bell et al., 2002; Miles et al., 2003; Harris et al., 2010) have produced conflicting results. Moreover, these studies have been limited by small samples of inpatients and proxy measures of violent behaviour (e.g. hostility, aggression). A recent meta-analysis of 12 studies involving 3873 subjects with severe mental illness – but not psychotic disorders specifically – reported a significant association between cannabis use and violence [pooled odds ratio (pOR) 3.0, 95% CI 2.0–4.5] (Dellazzizzo et al., 2019). To our knowledge, there have been no studies of depressants (besides alcohol) or hallucinogens.

To address the limitations of previous studies, we have investigated the associations of daily and nondaily use with violent behaviour for cannabis, stimulants, depressants and hallucinogens in two nationwide samples of individuals with psychotic disorders.

Methods

We used baseline data from two research projects: Genetic Risk and Outcome of Psychosis (GROUP) (Korver et al., 2012) and National Evaluation of the Development and Impact of Early Intervention Services (NEDEN) (Birchwood et al., 2014).
Setting and participants

**GROUP**

GROUP is conducted by four university medical centres (i.e. Amsterdam Medical Centre, Maastricht University Medical Centre+, University Medical Centre Groningen, University Medical Centre Utrecht) and affiliated mental health centres (k = 36) in the Netherlands. These centres are located in geographically representative areas of the country and provide access to treatment in a variety of settings (e.g. psychiatric hospitals, outpatient clinics) to approximately 75% of the population. Recruitment took place in 2004. To be eligible for participation, patients had to (i) be aged between 16 and 50, (ii) have a good command of the Dutch language and (iii) meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) (American Psychiatric Association, 2000) criteria for schizophrenia or another psychotic disorder. In accordance with standard local practice, DSM-IV-TR diagnoses were made with the Comprehensive Assessment of Symptoms and History (Andreasen et al., 1992) or Schedules for Clinical Assessment for Neuropsychiatry (Wing et al., 1990).

**NEDEN**

All individuals enrolled into Early Intervention Services (EIS) at five sites across England (i.e. Birmingham, Cornwall, Cambridge, Norwich, Lancashire) between 2005 and 2009 were invited to participate. Sites were chosen to reflect urban and rural differences. The Department of Health and Social Care requires that people receiving EIS are between 14 and 35 years old and present with a first episode of psychosis. No additional inclusion criteria were set. The Operationalized Criteria System (McGuffin et al., 1991) was used to determine International Statistical Classification of Diseases and Related Health Problems, Tenth Edition (ICD-10) (World Health Organization [WHO], 1992) diagnoses of mental disorders.

Measures

Information about the instruments’ psychometric properties can be found in the relevant publications for GROUP (Korver et al., 2012) and NEDEN (Birchwood et al., 2014). Unless otherwise specified, the reference period was the lifetime.

**GROUP**

Substance use: The Substance Abuse Module of the Composite International Diagnostic Interview (CIDI-SAM) (WHO, 1990) was used to measure the frequency (i.e. daily use, nondaily use, no use) and severity (i.e. problematic use, nonproblematic use, no use) of substance use. The CIDI-SAM distinguishes between the following categories of substances: (i) alcohol; (ii) cannabis; (iii) cocaine; (iv) stimulants (e.g. amphetamine, khat); (v) sedatives (e.g. pentobarbital, diazepam); (vi) opiates (e.g. heroin, codeine); (vii) inhalants (e.g. toluene, butane); (viii) phenycyclidine (PCP); (ix) psychedelics [e.g. lysergic acid diethylamide (LSD), mescaline]; and (x) other substances [e.g. amyl nitrite, 3,4-methylenedioxymethamphetamine (MDMA)]. Based on considerations of statistical power and similarities in psychopharmacological effects, we combined cocaine and stimulants as ‘stimulants’, sedatives, opiates and inhalants as ‘depressants’ and PCP and psychedelics as ‘hallucinogens’ (cf. Hill and Thomas, 2016). Cannabis, which has stimulant, depressant and hallucinogenic properties, was treated separately owing to the high prevalence of its use. We defined problematic alcohol use as an average intake of more than 18 standard drinks per week for men and more than 12 standard drinks per week for women during a minimum period of 2 weeks in the past year or 4 weeks at any other point in the past. These cutoffs reflect the median of several national guidelines and a consistent 1.5:1 male to female consumption ratio (Furtwaengler and de Visser, 2013). For other substances, problematic use corresponded to a DSM-IV-TR diagnosis of abuse or dependence.

Violent behaviour: Violent behaviour was established with the Life Chart Schedule (LCS) (Susser et al., 2000). Designed to record the development of symptoms, health care consumption and social functioning in schizophrenia patients, the LCS contains the following question regarding violence: ‘Did the patient physically attack or abuse someone else?’ The LCS was filled out based on review of clinical case notes and interviews with the patient and, if possible, one or both parents.

**NEDEN**

Substance use: A purposely designed questionnaire was used to assess substance use. For 15 substance categories, patients were asked whether they had used them: (i) almost every day; (ii) 1 to 3 times per week; (iii) less than once per week; (iv) 3 times or less; or (v) never. For the sake of consistency, we combined frequency categories ii, iii and iv as ‘nondaily use’ and refer to ‘almost every day’ as ‘daily’. The substance categories were rearranged as follows: (i) cannabis; (ii) stimulants (i.e. cocaine, amphetamine, khat); (iii) depressants (i.e. opiates, γ-hydroxybutyric acid, barbiturates, benzodiazepines, solvents, ‘poppers’); (iv) hallucinogens (i.e. LSD, psilocybin, ketamine); and (v) other substances (i.e. MDMA, ‘other’) (cf. Hill and Thomas, 2016).

Violent behaviour: Violent behaviour was ascertained from patient and clinician interviews using the Adverse Outcomes Questionnaire (AOQ). In the AOQ, a shortened version of the questionnaire used in the MacArthur Violence Risk Assessment Study (Steadman et al., 1998), violence is operationalized to encompass: (i) battery that resulted in physical injury; (ii) sexual assault; (iii) assault involving the use of a weapon; (iv) threats made with a weapon in hand; and (v) battery that did not result in physical injury. The AOQ referred to the past 12 months.

Analyses

First, we used logistic regression models to estimate the associations of daily and nondaily use with violent behaviour for cannabis, stimulants, depressants and hallucinogens in the GROUP and NEDEN samples separately. Three comparisons were made: (i) daily use v. nondaily or no use; (ii) daily use v. no use; and (iii) nondaily use v. no use. For theoretical reasons, we included the confounders age, sex and educational level (Lamsma and Harte, 2015). Educational level, indicating whether a patient had completed secondary school, served as a proxy for socioeconomic status (Maksimović et al., 2008). We only analysed complete cases. Depending on the scale of measurement, complete and incomplete cases were compared on each model variable with the χ²-test (dichotomous) or t test (continuous). To improve validity, we required models with at least 5 observations per cell in the 2 × 2 table of the exposure and outcome of interest.

We then combined the results for the GROUP and NEDEN samples in random-effects meta-analyses. The I² statistic was used as a measure of heterogeneity. Values of 25, 50 and 75%
denoted low, moderate and high levels of heterogeneity, respectively (Higgins et al., 2003).

For sensitivity analyses, we examined severity of use. Alcohol, which has consistently been found to increase violence risk in people with psychotic disorders (Witt et al., 2013), was used as a positive control.

The level of statistical significance was set at 5%. Analyses were carried out in STATA 12.1.

**Results**

Of the 1013 patients in the GROUP sample, 871 (86%) had data on all model variables and were thus included in the analyses. The corresponding numbers in the NEDEN sample were 1027 and 921 (90%), respectively. Complete cases differed significantly from incomplete cases on age \[ t_{(1011)} = 3.31, p = 0.001 \] in the GROUP sample (online Supplementary Table S1) and educational level \[ \chi^2 (1) = 3.89, p = 0.049 \] in the NEDEN sample (online Supplementary Table S2).

### Demographic and clinical characteristics of patients

#### GROUP

Demographic and clinical characteristics of the patients (online Supplementary Table S2).

Demographic and clinical characteristics of patients in the GROUP sample (online Supplementary Table S1) and educational level \[ \chi^2 (1) = 3.89, p = 0.049 \] in the NEDEN sample (online Supplementary Table S2).

#### NE DEN

The patients (N = 921) had a mean age of 22.8 years (S.D. = 4.8) and were predominantly male (n = 639, 69%). (Table 1). The most common diagnosis was schizophrenia (n = 478, 47%). Almost two thirds of the patients had used illicit substances (n = 589, 64%). The prevalence of violent behaviour was 22% (n = 204).

#### Primary analyses

**GROUP**

Daily use, compared with nondaily or no use, and nondaily use increased the adjusted odds of violent behaviour for all substance categories (Table 2). The increases were significant for daily use of stimulants [adjusted odds ratio (aOR) 2.2, 95% CI 1.3–3.8] and nondaily use of hallucinogens (aOR 1.8, 95% CI 1.2–2.7).

**NE DEN**

When comparing daily use with nondaily or no use, cannabis (aOR 1.8, 95% CI 1.3–2.5), stimulants (aOR 3.6, 95% CI 2.1–6.4), depressants (aOR 3.3, 95% CI 1.5–7.2) and hallucinogens (aOR 3.3, 95% CI 1.2–9.3) significantly increased the adjusted odds of violence (Table 2). Nondaily use increased the aORs for these substance categories as well, with that for stimulants reaching statistical significance (aOR 1.6, 95% CI 1.2–2.3).

#### Meta-analyses

Pooled across the GROUP and NE DEN samples, daily use of cannabis (pOR 1.6, 95% CI 1.2–2.0), stimulants (pOR 2.8, 95% CI 1.7–4.5) and depressants (pOR 2.2, 95% CI 1.1–4.5) significantly increased the odds of violence compared with nondaily or no use (Table 3). The same was found for nondaily use (compared with no use) of stimulants (pOR 1.6, 95% CI 1.2–2.0) and hallucinogens (pOR 1.5, 95% CI 1.1–2.1). Moderate heterogeneity was present for daily use of depressants in both comparisons (I^2 = 46%, 50%). Otherwise, heterogeneity was low (I^2 < 36%).

#### Sensitivity analyses

We observed no material differences in results after repeating the analyses in the GROUP sample with severity of use. As expected, alcohol increased the adjusted odds of violence (online Supplementary Table S3).

#### Discussion

In two nationwide samples totalling 1792 individuals with psychotic disorders, we investigated associations between frequency of use and violence for different categories of illicit substances.

---

### Table 1. Demographic and clinical characteristics of patients in the GROUP (N = 871) and NE DEN (N = 921) samples

| CHARACTERISTIC | GROUP   | NE DEN  |
|---------------|---------|---------|
| Demographic characteristics | | |
| Age, mean (s.a.) in years | 27.3 (7.1) | 22.8 (4.8) |
| Male | 673 (77) | 639 (69) |
| Caucasian | 679 (79) | 679 (74) |
| Completed secondary school | 753 (86) | 811 (88) |
| Clinical characteristics | | |
| Psychiatric diagnosis* | | |
| Schizophrenia | 602 (69) | 478 (47) |
| Schizoaffective disorder | 106 (12) | 70 (7) |
| Psychotic disorder NOS | 74 (8) | 190 (19) |
| Other | 89 (10) | 289 (28) |
| Age of onset, mean (s.a.) in years | 23.1 (6.5) | 21.3 (4.9) |
| Use of illicit substances | | |
| Daily | 430 (49) | 314 (34) |
| Cannabis | 411 (48) | 285 (31) |
| Stimulants | 68 (8) | 55 (6) |
| Depressants | 51 (6) | 28 (3) |
| Hallucinogens | 6 (1) | 15 (2) |
| Other | 23 (3) | 21 (2) |
| Nondaily | 427 (49) | 480 (52) |
| Cannabis | 170 (20) | 279 (30) |
| Stimulants | 198 (24) | 245 (27) |
| Depressants | 62 (8) | 89 (10) |
| Hallucinogens | 165 (20) | 161 (17) |
| Other | 212 (26) | 230 (25) |
| Violent behaviour | 179 (21) | 204 (22) |

s.a., standard deviation; NOS, not otherwise specified.
Data are n (%), unless otherwise stated.
*Psychiatric diagnoses were only available for the full NE DEN sample (N = 1027).
to treatment than those without these substance problems. Second, substance use may interfere with treatment. Individuals with problematic substance use are less likely to seek and adhere to treatment than those without these substance problems, with the possible exception of PCP.

Psychotic disorder (Di Forti et al., 2006). At the same time, substances may be used in an attempt to alleviate psychotic symptoms or unpleasant side effects of antipsychotics (Gregg et al., 2007). Self-medication increases the likelihood of avoidance or discontinuation of treatment and vice versa (Swartz et al., 1998). Substances may also reduce the therapeutic activity of antipsychotics (Lindsey et al., 2012). In the absence of effective treatment, positive symptoms may persist or worsen. Third, violence may occur during the commission of crimes to gain access to substances or the money to buy them (McGinty et al., 2016). Finally, users may become involved in illegal drug markets where violent behaviour is commonplace (Hodgins, 2008). Other explanations for the findings involve the use of multiple data sources increased the sensitivity of the results. Second, sampling was also independent of the exposures and outcome of interest. This enhanced the generalizability of the results. However, there are several limitations. First, causality cannot be inferred, as the temporal relationship between substance use and violent behaviour was not known and we did not control for other confounders besides age, sex and educational level. Second, we included individuals who had used substances belonging to different categories, which may have biased risk estimates. Exclusion would have made cell counts too low for meaningful analyses of most substance categories. Third, daily use was a proxy measure of SUD. However, similar results were obtained for DSM-IV-TR diagnoses.

### Table 2. Prevalence and risk of violent behaviour by different categories of illicit substances and frequency of their use in the GROUP (N=871) and NEDEN (N=921) samples

| Substance category | n (%) | aOR (95% CI)* |
|--------------------|-------|--------------|
|                    | DU    | NDU | NU | DU v. NDU or NU | DU v. NU | NDU v. NU |
| GROUP              |       |     |    |                  |           |           |
| Cannabis           | 99 (24)| 36 (21) | 44 (15) | 1.4 (1.0–1.9) | 1.5 (1.0–2.3) | 1.3 (0.8–2.2) |
| Stimulants         | 25 (37)| 48 (24) | 98 (17) | 2.2 (1.3–3.8) | 2.6 (1.5–4.5) | 1.5 (1.0–2.2) |
| Depressants        | 15 (29)| 18 (29) | 134 (19) | 1.6 (0.9–3.1) | 1.7 (0.9–3.3) | 1.7 (0.9–3.0) |
| Hallucinogens      | 3 (50) | 46 (28) | 113 (17) | – | – | 1.8 (1.2–2.7) |
| Other              | 8 (35) | 57 (27) | 100 (17) | 1.9 (0.8–4.6) | 2.4 (1.0–5.8) | 1.7 (1.2–2.6) |
| NEDEN              |       |     |    |                  |           |           |
| Cannabis           | 88 (30)| 60 (21) | 61 (17) | 1.8 (1.3–2.5) | 2.0 (1.3–2.9) | 1.2 (0.8–1.8) |
| Stimulants         | 26 (46)| 71 (28) | 112 (17) | 3.6 (2.1–6.4) | 4.3 (2.4–7.8) | 1.6 (1.2–2.3) |
| Depressants        | 13 (43)| 23 (26) | 173 (21) | 3.3 (1.5–7.2) | 3.4 (1.6–7.3) | 1.2 (0.7–2.0) |
| Hallucinogens      | 7 (47) | 44 (27) | 158 (21) | 3.3 (1.2–9.3) | 3.4 (1.2–9.6) | 1.3 (0.9–1.9) |
| Other              | 10 (45)| 65 (27) | 134 (19) | 3.4 (1.4–8.2) | 3.9 (1.6–9.3) | 1.5 (1.0–2.1) |

aOR, adjusted odds ratio; CI, confidence interval; DU, daily use; NDU, nondaily use; NU, no use.

Overall, daily and nondaily use of cannabis, stimulants, depressants, and hallucinogens were found to increase violence risk.

There are at least four ways in which substance use may lead to violent behaviour in psychotic disorders. First, psychopharmacological effects of intoxication with or withdrawal from substances (e.g. disinhibition, intensification of negative emotions) may lower the threshold for violence (Kuhns and Clodfelter, 2009). Substance use may also induce or exacerbate positive symptoms (e.g. delusions, hallucinations) (Winklbaur et al., 2006), which are risk factors for violent behaviour (Witt et al., 2013). This may be particularly relevant for cannabis and hallucinogens. The former has been found to increase the risk of developing a psychotic disorder (Di Forti et al., 2019), and the latter – with the possible exception of PCP – are thought not to increase violence risk in the general population (Tomlinson et al., 2016). Second, substance use may interfere with treatment. Individuals with problematic substance use are less likely to seek and adhere to treatment than those without these substance problems (Winklbaur et al., 2006). At the same time, substances may be used in an attempt to alleviate psychotic symptoms or unpleasant side effects of antipsychotics (Gregg et al., 2007). Self-medication increases the likelihood of avoidance or discontinuation of treatment and vice versa (Swartz et al., 1998). Substances may also reduce the therapeutic activity of antipsychotics (Lindsey et al., 2012). In the absence of effective treatment, positive symptoms may persist or worsen. Third, violence may occur during the commission of crimes to gain access to substances or the money to buy them (McGinty et al., 2016). Finally, users may become involved in illegal drug markets where violent behaviour is commonplace (Hodgins, 2008). Other explanations for the findings are confounding or mediation by biological (e.g. genetics, neurobiological abnormalities), psychological (e.g. cognitive impairment, personality pathology) or environmental (e.g. childhood maltreatment, erosion of social support) risk factors (Lamsma and Harte, 2015).

As far as we know, this is the largest study to investigate the relationship between use of illicit substances and violent behaviour in psychotic disorders. It has several strengths. First, the samples were drawn from diverse geographic areas and care settings. Sampling was also independent of the exposures and outcome of interest. This enhanced the generalizability of the results. Second, the use of multiple data sources increased the sensitivity of the LCS and AOQ as measures of violence. Finally, the findings for alcohol (as a positive control) were in the expected direction, supporting the validity of the design. However, there are several limitations. First, causality cannot be inferred, as the temporal relationship between substance use and violent behaviour was not known and we did not control for other confounders besides age, sex and educational level. Second, we included individuals who had used substances belonging to different categories, which may have biased risk estimates. Exclusion would have made cell counts too low for meaningful analyses of most substance categories. Third, daily use was a proxy measure of SUD. However, similar results were obtained for DSM-IV-TR diagnoses.
of abuse and dependence in the GROUP sample. Fourth, the definition and reference period for violence varied between GROUP and NEDEN. The more stringent definition and shorter reference period may explain why aORs were slightly higher in the NEDEN sample. Fifth, missing data may have limited the validity of the results. Sixth, the results of the meta-analyses should be treated with some caution: the estimation of the between-study variance, which is used in the calculation of the pooled effect size and its confidence interval, may be inaccurate when the number of studies is small (Borenstein et al., 2009). Seventh, we were unable to analyse PCP separately. Either too few patients had used PCP (GROUP) or no specific information was recorded for PCP (NEDEN). Finally, there has been a large increase in the use of novel psychoactive substances (NPS) in the years following data collection (Tracy et al., 2017). NPS are synthetic compounds designed to mimic the psychopharmacological effects of traditional substances (Millano et al., 2016). Therefore, we hypothesize that NPS increase violence risk.

A clinical implication of the findings is that violence risk assessment in psychotic disorders should target any substance use. For structured instruments, it should be determined whether items for SUD and subthreshold use of different substance categories have incremental validity over a single item for SUD. The findings also suggest that interventions, which currently focus on SUD, may assist in the prevention of violent behaviour in patients with subthreshold use (Chang et al., 2016). To clarify causal mechanisms, we recommend that studies further isolate the psychopharmacological effects of substances, use prospective designs and test for additional confounders and mediators.

Supplementary material. The supplementary material for this article can be found at https://doi.org/10.1017/S0033291719002125.

Financial support. GROUP was funded by the Geestkracht programme of The Netherlands Organisation for Health Research and Development (10-000-1001) and matching funds from the coordinating university medical centres (i.e. Academic Medical Centre, Maastricht University Medical Centre+, University Medical Centre Groningen, University Medical Centre Utrecht), their affiliated mental health centres (i.e. Altrecht, Arkin, Delta, Dimence, Dijk en Duin, Erasmus UMC, GGNet, GGZ Breburg, GGZ Centraal, GGZ Drenthe, GGZ Eindhoven and De Kempen, GGZ Friesland, GGZ inGeest, Mondriaan, GGZ Noord-Holland-Noord, GGZ Oost-Brabant, GGZ Overpelt, GGZ Rivierduinen, Lentis, Mediant GGZ, Met GGZ, Parnassia Psycho-Medical Centre, Psychiatric Centre Ziekenhuis, Psychiatric Hospital Sancta Maria, Public Centre for Mental Health Rekem, The Collaborative Antwerp Psychiatric Research Institute, Vincent van Gogh voor Geestelijke Gezondheid, Virenze riag, University Psychiatric Centre Sint Jozef, Yulius, Zuydland GGZ) and participating pharmaceutical companies (i.e. Lundbeck, AstraZeneca, Eli Lilly, Janssen Cilag). NEDEN was funded by the United Kingdom Department of Health and Social Care (PO261680). JI received funding from the Prins Bernhard Cultuurfonds and Dr Hendrik Muller Fonds. SF is funded by a Wellcome Trust Senior Research Fellowship in Clinical Science (202836/Z/16/Z).

Conflict of interest. None.

References

American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington: Author.
Andreasen NC, Flaum M and Arndt S (1992) The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Archives of General Psychiatry 49, 615–623.
Bell M, Greig T, Gill P, Whelahan H and Bryson G (2002) Work rehabilitation and patterns of substance use among persons with schizophrenia. Psychiatric Services 53, 63–69.
Birchwood M, Lester H, McCarthy L, Jones P, Fowler D, Amos T, Freemantle N, Sharma V, Lavis A, Singh S and Marshall M (2014) The UK national evaluation of the development and impact of Early Intervention Services (the National EDEN studies): study rationale, design and baseline characteristics. Early Intervention in Psychiatry 8, 59–67.
Borenstein M, Hedges LV, Higgins JP and Rothstein HR (2009) Introduction to meta-analysis. Chichester: Wiley.
Chang Z, Lichtenstein P, Langstrom N, Larsson H and Fazel S (2016) Association between prescription of major psychotropic medications and violent reoffending after prison release. JAMA 316, 1798–1807.
Dellazzio I, Potvin S, Beaudoin M, Luigi M, Dou BY, Giguère CÉ and Dumais A (2019) Cannabis use and violence in patients with severe mental illnesses: a meta-analytical investigation. Psychiatry Research 274, 42–48.
Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quiqley H, Rodrigue V, Jongsma HE, Ferraro L, La Cascia C, La Barbera D, Tarricone I, Berardi D, Szöke A, Arango C, Tortelli A, Velthorst E, Bernardo M, Del-Ben CM, Menezes PR, Selten JP, Jones PB, Kirkbride JB, Rutten BP, de Haan L, Sham PC, van Os J, Lewis CM, Linskey M, Morgan C, Murray RM and EU-GEI WP2 Group (2019) The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. The Lancet Psychiatry 6, 427–436.
Fazel S, Gulati G, Linsell L, Geddes JR and Grann M (2009) Schizophrenia and violence: systematic review and meta-analysis. PLoS Medicine 6, e1000120.
Furtwaengler NA and de Visser RO (2013) Lack of international consensus in low-risk drinking guidelines. Drug and Alcohol Review 32, 11–18.
Gregg I, Barrowclough C and Haddock G (2007) Reasons for increased substance use in psychosis. Clinical Psychology Review 27, 494–510.
Harris AW, Large MM, Redoblado-Hodge A, Nielsen O, Anderson J and Brennan J (2010) Clinical and cognitive associations with aggression in the first episode of psychosis. Australian and New Zealand Journal of Psychiatry 44, 85–93.
Higgins J, Thompson S, Deeks J and Altman D (2003) Measuring inconsistency in meta-analyses. BMJ 327, 557–560.
Hill SI and Thomas SH (2016) Drugs of abuse. Medicine 44, 160–169.
Hodgins S (2008) Violent behaviour among people with schizophrenia: a framework for investigations of causes, and effective treatment, and prevention. Philosophical Transactions of the Royal Society B: Biological Sciences 363, 2505–2518.
Koen L, Kinnear CJ, Corfield VA, Emsley RA, Jordaan E, Keyner N, Moollan-Smook JC, Stein DJ and Niehaus DJ (2004) Violence in male patients with schizophrenia: risk markers in a South African population. Australian and New Zealand Journal of Psychiatry 38, 254–259.
Korver N, Quee PJ, Boos HB, Simons CJ, de Haan L and GROUP investigators (2012). Genetic Risk and Outcome of Psychosis (GROUP), a multi-site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. International Journal of Methods in Psychiatric Research 21, 205–221.
Kuhns JB and Clodfelter TA (2009) Illicit drug-related psychopharmacological violence: the current understanding within a causal context. Aggression and Violent Behavior 14, 69–78.
Lamsma J and Harte JM (2015) Violence in psychosis: conceptualizing its causal relationship with risk factors. Aggression and Violent Behavior 24, 75–82.
Lindsey WT, Stewart D and Childress D (2012) Drug interactions between common illicit drugs and prescription therapies. The American Journal of Drug and Alcohol Abuse 38, 334–343.
Maksimović MŽ, Vlajinac HD, Radak DJ, Maksimović JM, Marinković JM and Jorga JB (2008) Association of socioeconomic status measured by education and risk factors for carotid atherosclerosis: cross-sectional study. Croatian Medical Journal 49, 824–831.
McIntyre EE, Choksy S and Wintemute GJ (2016) The relationship between controlled substances and violence. Epidemiological Reviews 38, 5–31.
McGuffin P, Farmer A and Harvey I (1991) A polydiagnostic application of operational criteria in studies of psychotic illness. Archives of General Psychiatry 48, 764–770.

Miles H, Johnson S, Ampomah-Afuwape S, Finch E, Leese M and Thornicroft G (2003) Characteristics of subgroups of individuals with psychotic illness and a comorbid substance use disorder. Psychiatric Services 54, 554–561.

Miliano C, Serpelloni G, Rimondo C, Mereu M, Marti M and De Luca MA (2016) Neuropharmacology of new psychoactive substances (NPS): focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants. Frontiers in Neuroscience 10, 153.

Moulin V, Baumann P, Gholamrezaee M, Alameda L, Palix J, Gasser J and Conus P (2018) Cannabis, a significant risk factor for violent behavior in the early phase psychosis. Two patterns of interaction of factors increase the risk of violent behavior: cannabis use disorder and impulsivity; cannabis use disorder, lack of insight and treatment adherence. Frontiers in Psychiatry 9, 294.

Oluwoye O, Monroe-DeVita M, Burduli E, Chwastiak L, McPherson S, McClelan JM and McDonell MG (2019) Impact of tobacco, alcohol and cannabis use on treatment outcomes among patients experiencing first episode psychosis: data from the national RAISE-ETP study. Early Intervention in Psychiatry 13, 142–146.

Steadman HJ, Mulvey EP, Monahan J, Robbins PC, Appelbaum PS, Grasso T, Roth LH and Silver E (1998) Violence by people discharged from acute psychiatric inpatient facilities and by others in the same neighborhoods. Archives of General Psychiatry 55, 393–401.

Suss E, Finnerty M, Mojtahai R, Yale S, Conover S, Goetz R and Amador X (2000) Reliability of the life chart schedule for assessment of the long-term course of schizophrenia. Schizophrenia Research 42, 67–77.

Swartz MS, Swanson JE, Hiday VA, Borum R, Wagner HR and Burns BJ (1998) Violence and severe mental illness: the effects of substance abuse and nonadherence to medication. The American Journal of Psychiatry 155, 226–231.

Tomlinson MF, Brown M and Hoaken PN (2016) Recreational drug use and human aggressive behavior: a comprehensive review since 2003. Aggression and Violent Behavior 27, 9–29.

Tracy DK, Wood DM and Baumeister D (2017) Novel psychoactive substances: types, mechanisms of action, and effects. BMJ 356, i6848.

Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, Jablenski A, Regier D and Sartorius N (1990) SCAN: schedules for clinical assessment in neuropsychiatry. Archives of General Psychiatry 47, 589–593.

Winklbaur B, Ebner N, Sachs G, Thau K and Fischer G (2006) Substance abuse in patients with schizophrenia. Dialogues in Clinical Neuroscience 8, 37–43.

Witt K, Van Dorn RA and Fazel S (2013) Risk factors for violence in psychosis: systematic review and meta-regression analysis of 110 studies. PLoS One 8, 1–15.

World Health Organization (1992) The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization.

World Health Organization (1990) Composite International Diagnostic Interview. Geneva: World Health Organization.